WO2009124733A8 - Substituierte sulfonamid-derivate - Google Patents

Substituierte sulfonamid-derivate Download PDF

Info

Publication number
WO2009124733A8
WO2009124733A8 PCT/EP2009/002578 EP2009002578W WO2009124733A8 WO 2009124733 A8 WO2009124733 A8 WO 2009124733A8 EP 2009002578 W EP2009002578 W EP 2009002578W WO 2009124733 A8 WO2009124733 A8 WO 2009124733A8
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonamide derivatives
substituted sulfonamide
producing
substituted
drugs
Prior art date
Application number
PCT/EP2009/002578
Other languages
English (en)
French (fr)
Other versions
WO2009124733A1 (de
Inventor
GmbH Grünenthal
Stefan OBERBÖRSCH
Melanie Reich
Stefan Schunk
Michael Franz-Martin Engels
Ruth Jostock
Tieno Germann
Jean De Vry
Klaus Schiene
Sabine Hees
Original Assignee
Gruenenthal Gmbh
Oberboersch Stefan
Melanie Reich
Stefan Schunk
Michael Franz-Martin Engels
Ruth Jostock
Tieno Germann
Jean De Vry
Klaus Schiene
Sabine Hees
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh, Oberboersch Stefan, Melanie Reich, Stefan Schunk, Michael Franz-Martin Engels, Ruth Jostock, Tieno Germann, Jean De Vry, Klaus Schiene, Sabine Hees filed Critical Gruenenthal Gmbh
Priority to RU2010145013/04A priority Critical patent/RU2503674C2/ru
Priority to MX2010011095A priority patent/MX2010011095A/es
Priority to JP2011503376A priority patent/JP2011517459A/ja
Priority to AU2009235634A priority patent/AU2009235634B8/en
Priority to EP09730791A priority patent/EP2262792A1/de
Priority to CA2720793A priority patent/CA2720793A1/en
Priority to CN200980121445.2A priority patent/CN102056919B/zh
Publication of WO2009124733A1 publication Critical patent/WO2009124733A1/de
Priority to IL208519A priority patent/IL208519A0/en
Publication of WO2009124733A8 publication Critical patent/WO2009124733A8/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Die Erfindung betrifft substituierte Sulfonamid-Derivate, Verfahren zu deren Herstellung, Arzneimittel enthaltend diese Verbindungen und die Verwendung von substituierten Sulfonamid-Derivaten zur Herstellung von Arzneimitteln.
PCT/EP2009/002578 2008-04-08 2009-04-08 Substituierte sulfonamid-derivate WO2009124733A1 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
RU2010145013/04A RU2503674C2 (ru) 2008-04-08 2009-04-08 Замещенные производные сульфонамида
MX2010011095A MX2010011095A (es) 2008-04-08 2009-04-08 Derivados de sulfonamidas sustituidos.
JP2011503376A JP2011517459A (ja) 2008-04-08 2009-04-08 置換されたスルホンアミド誘導体
AU2009235634A AU2009235634B8 (en) 2008-04-08 2009-04-08 Substituted sulfonamide derivatives
EP09730791A EP2262792A1 (de) 2008-04-08 2009-04-08 Substituierte sulfonamid-derivate
CA2720793A CA2720793A1 (en) 2008-04-08 2009-04-08 Substituted sulfonamide derivatives
CN200980121445.2A CN102056919B (zh) 2008-04-08 2009-04-08 取代的磺酰胺衍生物
IL208519A IL208519A0 (en) 2008-04-08 2010-10-06 Substituted sulfonamide derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08006957 2008-04-08
EP08006957.8 2008-04-08

Publications (2)

Publication Number Publication Date
WO2009124733A1 WO2009124733A1 (de) 2009-10-15
WO2009124733A8 true WO2009124733A8 (de) 2010-11-18

Family

ID=39967424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/002578 WO2009124733A1 (de) 2008-04-08 2009-04-08 Substituierte sulfonamid-derivate

Country Status (14)

Country Link
US (1) US8318769B2 (de)
EP (1) EP2262792A1 (de)
JP (1) JP2011517459A (de)
CN (1) CN102056919B (de)
AR (1) AR071363A1 (de)
AU (1) AU2009235634B8 (de)
CA (1) CA2720793A1 (de)
CL (1) CL2009000851A1 (de)
IL (1) IL208519A0 (de)
MX (1) MX2010011095A (de)
PE (1) PE20091782A1 (de)
RU (1) RU2503674C2 (de)
TW (1) TW200948801A (de)
WO (1) WO2009124733A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2462464C2 (ru) * 2006-09-29 2012-09-27 Грюненталь Гмбх Замещенные сульфамидные производные
US8404741B2 (en) * 2010-02-19 2013-03-26 Bristol-Myers Squibb Company Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
JP2014159375A (ja) * 2011-06-15 2014-09-04 Takeda Chem Ind Ltd アゼパン化合物
CN107266378B (zh) * 2016-04-06 2020-08-21 南开大学 含有磺酰基结构三嗪酮衍生物及其制备方法和在杀虫、杀菌方面的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
IL132736A0 (en) * 1997-05-22 2001-03-19 Searle & Co 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
ES2327338T3 (es) * 2003-03-25 2009-10-28 Laboratoires Fournier Sa Derivados de bencenosulfonamida, su procedimiento de preparacion y su utilizacion para el tratamiento del dolor.
MXPA05010884A (es) * 2003-04-10 2007-01-15 Amgen Inc Compuestos biciclicos que tienen afinidad por receptores de bradicinina y composiciones farmaceuticas de los mismos.
CA2522084A1 (en) * 2003-04-10 2004-10-28 Amgen Inc. Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin
WO2007140383A2 (en) 2006-05-30 2007-12-06 Neurogen Corporation Spirocyclic sulfonamides and related compounds
DE102006039003A1 (de) * 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
WO2008024692A1 (en) 2006-08-23 2008-02-28 Neurogen Corporation N-oxide aryl sulfones and sulfoxides
RU2462464C2 (ru) * 2006-09-29 2012-09-27 Грюненталь Гмбх Замещенные сульфамидные производные
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
DE102007020492A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
DE102007020493A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
TW200940528A (en) * 2008-03-05 2009-10-01 Gruenenthal Gmbh Substituted sulfonamide derivatives
TW200940523A (en) * 2008-03-17 2009-10-01 Gruenenthal Gmbh Substituted sulfonamide derivatives
CL2009000852A1 (es) * 2008-04-08 2009-07-17 Gruenenthal Gmbh Compuestos derivados de sulfonamidas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento del dolor agudo, cronico, inflamatorio, entre otros.
RS53941B1 (en) * 2009-01-12 2015-08-31 Pfizer Limited SULFONAMID DERIVATIVES

Also Published As

Publication number Publication date
EP2262792A1 (de) 2010-12-22
JP2011517459A (ja) 2011-06-09
AU2009235634A8 (en) 2013-05-23
CN102056919A (zh) 2011-05-11
MX2010011095A (es) 2010-11-05
CN102056919B (zh) 2014-03-12
AU2009235634B2 (en) 2013-04-18
TW200948801A (en) 2009-12-01
AR071363A1 (es) 2010-06-16
AU2009235634A1 (en) 2009-10-15
PE20091782A1 (es) 2009-11-15
WO2009124733A1 (de) 2009-10-15
US8318769B2 (en) 2012-11-27
CA2720793A1 (en) 2009-10-15
US20090264400A1 (en) 2009-10-22
IL208519A0 (en) 2010-12-30
CL2009000851A1 (es) 2009-07-17
AU2009235634B8 (en) 2013-05-23
RU2010145013A (ru) 2012-05-20
RU2503674C2 (ru) 2014-01-10

Similar Documents

Publication Publication Date Title
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
MX2010010407A (es) Derivados de 4-aminociclohexanos sustituidos.
WO2010115552A8 (en) Bispecific anti-erbb-3/anti-c-met antibodies
WO2008009415A3 (de) 4-heteroaryl-substituierte 1-aminocyclohexan-1- und cyclohexen-1-derivate mit wirkung auf das opiod rezeptor system
WO2009156462A3 (en) Organic compounds
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
IL211541A0 (en) Co-crystal compositions, methods of producing the same and uses thereof
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2010120994A3 (en) Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
WO2010102778A3 (de) Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
WO2011133504A3 (en) Nanozymes, methods of making nanozymes, and methods of using nanozymes
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2009115084A3 (de) Pyrrolopyrimidin-derivate und deren verwendungen
WO2006122769A3 (de) Substituierte spiro-verbindungen und deren verwendung zur herstellung von arzneimitteln gegen schmerz
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2010049449A3 (en) Novel salts of sunitinib
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
WO2009002538A3 (en) Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2008065282A3 (fr) Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
WO2008075205A3 (en) Improved process for the preparation of voriconazole
WO2009124733A8 (de) Substituierte sulfonamid-derivate

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980121445.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09730791

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009730791

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2720793

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011503376

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/011095

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009235634

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010145013

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2009235634

Country of ref document: AU

Date of ref document: 20090408

Kind code of ref document: A